氟哌噻吨美利曲辛治疗感觉敏感性膀胱过度活动症的疗效研究  

Study on the efficacy of flupentixol melitracen in the treatment of hypersensitive overactive bladder syndrome

作　　者：俞江 王博[2] 吕婷婷[1] 顾寅珺[1] 方伟林[1] 蒋晨[1] 吕坚伟[1] YU Jiang;WANG Bo;LV Tingting;GU Yinjun;FANG Weilin;JIANG Chen;LV Jianwei(Department of Urology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200127,China;Department of Urology,Suzhou Kowloon Hospital,Shanghai Jiao Tong University School of Medicine)

机构地区：[1]上海交通大学医学院附属仁济医院泌尿外科,上海200127 [2]上海交通大学医学院附属苏州九龙医院泌尿外科

出　　处：《临床泌尿外科杂志》2020年第12期975-979,共5页Journal of Clinical Urology

基　　金：上海市综合医院中西医结合专项建设项目(No:ZHYY-ZXYJHZX-201601);上海市卫生和计划生育委员会科研课题项目(No:201840114)。

摘　　要：目的:探讨氟哌噻吨美利曲辛治疗感觉敏性膀胱过度活动症(OAB)的临床疗效。方法:2019年7月~2019年12月门诊就诊的OAB患者中,选取临床以时刻尿意感为主要症状、尿动力检查膀胱初始尿意容量<150 mL且无明显逼尿肌过度活动的女性OAB患者72例,随机分为氟哌噻吨美利曲辛试验组36例和托特罗定对照组36例,试验组每天口服氟哌噻吨美利曲辛1片(含氟哌噻吨0.5 mg和美利曲辛10 mg),对照组每天口服托特罗定缓释片4 mg,两组治疗周期均为12周,每组患者治疗前后分别评估24 h排尿日记、OABSS评分、OAB-V8评分、生活质量QOL评分以及尿动力检查,分析比较两组的临床疗效及安全性。结果:试验组和对照组在治疗前患者OABSS评分、OAB-V8评分以及尿动力检测膀胱初始尿意容量差异均无统计学意义(P>0.05);试验组和对照组治疗12周后OABSS评分分别为(4.3±1.9)分和(4.8±2.1)分(P>0.05)、OAB-V8评分分别为(9.3±4.9)分和(11.6±4.7)分(P<0.05)、尿动力膀胱初始尿意容量分别为(165.5±31.8)mL和(129.0±33.6)mL(P<0.01);试验组和对照组的治疗有效率分别为86.1%(31/36)和63.8%(23/36)(P<0.05)。两组患者均未出现严重不良反应。结论:氟哌噻吨美利曲辛治疗感觉敏感性OAB的疗效优于托特罗定,且安全性好,为感觉敏感性OAB的临床治疗提供了新的思路。Objective:To explore the efficacy of flupentixol melitracen on female hypersensitivity overactive bladder syndrome(OAB).Method:From July 2019 to December 2019,a total of 72 outpatient patients were chosen and randomly divided into an experimental group and a control group when the following conditions were met:patients complained of persistent micturition desire and urodynamics showed increased bladder sensation without detrusor overactivity.Thirty-six cases in experimental group were treated with flupentixol melitracen(flupentixol 0.5 mg and melitracen 10 mg)orally once daily,while 36 cases in control group were treated with tolterodine 4 mg once daily.Voiding diary,OABSS score,OAB-V8 score,QOL and urodynamics were assessed for each group after 12 weeks.Result:The OABSS,OAB-V8 and the volume of first sense of filling period between two groups showed no difference(P>0.05)before therapy.Twelve weeks later,OABSS of experimental group and control group were(4.3±1.9)and(4.8±2.1),respectively(P>0.05).OAB-V8 of the two groups were(9.3±4.9)and(11.6±4.7),respectively(P<0.05).First sense volume of filling period was(165.5±31.8)ml in the experimental group and(129.0±33.6)ml in the control group(P<0.01).The effective rate was 86.1%(31/36)in the experimental group and 63.8%(23/36)in the control group(P<0.05).There was no severely adverse reactions.Conclusion:This study revealed flupentixol melitracen had better efficacy than tolterodine in the treatment of female hypersensitivity OAB.Our findings provide a new approach to the treatment of hypersensitivity OAB and has good security.

关 键 词：感觉敏感性 膀胱过度活动症 氟哌噻吨美利曲辛 托特罗定 

分 类 号：R694[医药卫生—泌尿科学]